
As you explore the world of Biovie stock, it's essential to stay up-to-date on the company's latest developments. Biovie is a biotechnology company that focuses on developing innovative treatments for various diseases.
Biovie's stock is listed on the NASDAQ exchange under the ticker symbol BVIE. The company's headquarters is located in San Francisco, California.
To stay informed about Biovie's progress, you can check the company's website or visit reputable financial websites that provide real-time stock quotes.
Intriguing read: S B I Card Share Price
Expand your knowledge: Goldman Stock Quote
Financial Performance
Biovie Inc's financial performance has been underwhelming, with a diluted earnings per share (EPS) of -5.08 for the trailing 12 months.
The company has seen no revenue growth year-over-year, which suggests that they're not expanding their customer base or increasing sales.
Earnings growth has also been stagnant, with a 0% year-over-year change.
This lack of growth is concerning, as it indicates that the company is not generating more profits from their operations.
Here are some key financial metrics for Biovie Inc:
Stock Information
BIVI stock has a previous close of $1.78, which is the price at which the stock last traded.
The stock's day range is between $1.63 and $1.83, showing a relatively small fluctuation in price over the course of the day.
BIVI's year range is quite significant, spanning from $1 to $18, indicating a substantial difference in stock value over the past year.
The company's market capitalization is approximately $31.6 million, which can give you an idea of its size and value.
BIVI is listed on the NASDAQ exchange, which is one of the most well-known and respected stock exchanges in the world.
Here's a summary of BIVI's stock performance in a table:
BIVI's stock performance is just one aspect of the company's overall picture.
Investor Information
As a shareholder, you'll want to know who owns BioVie. The company's shareholder breakdown is quite diverse, with 86.44% of shares held by freefloat, meaning they're not affiliated with any particular individual or group.
Terren S. Peizer is the largest individual shareholder, holding 13.04% of the company. He's followed closely by Altium Capital Management LP, which owns 11.16% of BioVie.
Here's a breakdown of the top shareholders:
Dividend Calendar
As an investor, it's essential to stay informed about the dividend calendar of the companies you're interested in. BioVie Inc's dividend calendar is quite straightforward, with a consistent payout history.
The company has consistently paid out $0.00 per share since 2014, with no change in dividend yield.
Looking at the dividend calendar, you'll notice that BioVie Inc has been paying out dividends every year since 2014. The dividend payout has remained the same at $0.00 per share.
Here's a breakdown of the dividend calendar for BioVie Inc:
The currency for all dividend payouts is USD, and the dividend yield remains at 0.00.
Shareholder
As we dive into the world of investor information, let's take a closer look at the shareholder structure of BioVie. The free float percentage is a significant 86.44%, indicating a relatively open ownership structure.
The largest shareholder is Terren S. Peizer, holding 13.04% of the company. This suggests a strong individual presence in the company's decision-making process.
Altium Capital Management LP is another major shareholder, owning 11.16% of the company. This highlights the importance of institutional investors in the company's ownership structure.
Here's a breakdown of the top shareholders:
These shareholders play a crucial role in shaping the company's direction and making key decisions.
Proposed Public
BioVie Inc. has proposed a public offering, which is a way for the company to raise capital by issuing new shares of stock to the public.
The proposed public offering was announced on September 23, 2024, and it's a significant step for a clinical-stage company like BioVie Inc. that's developing innovative drug therapies.
BioVie Inc. plans to use the net proceeds from the public offering for working capital and general corporate purposes. This will help the company fund its operations and continue to develop its drug therapies.
The company's focus on innovative drug therapies for the treatment of advanced liver disease and other conditions is a promising area of research and development.
Readers also liked: Ianthus Capital Holdings Inc Stock Price
Frequently Asked Questions
Is BioVie a good stock to buy?
BioVie is considered a strong buy opportunity by analysts, with a consensus rating of "Buy" compared to a "Moderate Buy" average for the medical sector. Learn more about why analysts favor BioVie over other medical companies.
What is the stock price forecast for BioVie in 2025?
According to the forecast, BioVie's share price is predicted to reach $30.00 by July 1, 2025, representing a potential upside of 1,308.45% from the current price of $2.13. This significant growth potential makes BioVie a stock worth considering for investors.
Why is BIVI stock down?
BioVie (BIVI) stock is down due to a failed Phase 3 clinical trial of its Alzheimer's treatment candidate, which did not meet statistical significance. This disappointing result has led to a significant decline in the company's stock value.
Featured Images: pexels.com


